Dose-exposure-response relationship between AZD6738 and peripheral monocytes.
Pierce A, Berges A, Cheung S, Standifer N, Ross G, Smith S, Hollingsworth S, Krebs M, Postel-Vinay S, Bang Y, El-Khoueiry A, Abida W, Sundar R, Carter L, Castanon-Alvarez E, Im S, Lopez J, Yap T, Harrington K, Soria J. Dose-exposure-response relationship between AZD6738 and peripheral monocytes. Journal Of Clinical Oncology 2017, 35: e14063-e14063. DOI: 10.1200/jco.2017.35.15_suppl.e14063.Peer-Reviewed Original ResearchDose-exposure-response relationshipPeripheral monocytesPARP-1 inhibitor olaparibPD-L1 inhibitor durvalumabPeripheral blood cell subpopulationsPhase 2 doseFlow cytometry characterizationPARP-1Dose-dependent mannerBlood cell subpopulationsPhosphatidylinositol 3-kinase-related kinasesPD-L1Peripheral pharmacokineticsInhibitor olaparibPeripheral bloodDrug exposureBone marrowPharmacodynamic effectsPharmacokinetic/pharmacodynamic relationshipsSurrogate markerClinical studiesMonocyte countMonocyte levelsPrecursor proliferationDurvalumab